×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
📊
Experiments
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
Vision
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
Vision
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: Anti-Amyloid Antibody Clinical Trials
therapeutic
1,616 words
KG: Anti-Amyloid Antibody Clinical Trials
2026-03-21
kind:therapeutic
section:therapeutics
state:published
Contents
Anti-Amyloid Antibody Clinical Trials
💊
Therapeutic Info
Name
Anti-Amyloid Antibody Clinical Trials
Summary
Page for Anti-Amyloid Antibody Clinical Trials
Knowledge Graph
Related Hypotheses (18)
Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
Score: 0.57
Synthetic Biology BBB Endothelial Cell Reprogramming
Score: 0.57
Circadian-Synchronized LRP1 Pathway Activation
Score: 0.53
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46
SASP-Driven Aquaporin-4 Dysregulation
Score: 0.59
Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54
Aquaporin-4 Polarization Rescue
Score: 0.51
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49
APOE Isoform Expression Across Glial Subtypes
Score: 0.48
Magnetosonic-Triggered Transferrin Receptor Clustering
Score: 0.47
Pericyte Contractility Reset via Selective PDGFR-β Agonism
Score: 0.44
APOE Isoform Conversion Therapy
Score: 0.44
LRP1-Dependent Tau Uptake Disruption
Score: 0.44
Show 13 more
Related Analyses (8)
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · completed
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · completed
Show 3 more
Related Experiments (30)
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
Show 25 more
See Also (15)
Wnt/β-Catenin Signaling Pathway in Neurodegeneration
mechanism · Pages share 3 hypotheses
WNK1-Bilirubin Signaling in Neuroinflammation and Neuro
mechanism · Pages share 3 hypotheses
vip-vasoactive-intestinal-peptide-signaling-neurodegene
mechanism · Pages share 3 hypotheses
VEGF Signaling and Cerebral Angiogenesis in Neurodegene
mechanism · Pages share 3 hypotheses
Vagus Nerve Pathway in Neurodegeneration
mechanism · Pages share 3 hypotheses
Ubiquitin-Proteasome System Dysfunction in Neurodegener
mechanism · Pages share 3 hypotheses
ubiquitin-proteasome-dysfunction-neurodegeneration
mechanism · Pages share 3 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
mechanism · Pages share 3 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
mechanism · Pages share 3 hypotheses
Therapeutic Targets in Neurodegeneration
mechanism · Pages share 3 hypotheses
Tertiary Lymphoid Organs in Neurodegeneration
mechanism · Pages share 3 hypotheses
T-Cell Dysfunction in Neurodegeneration
mechanism · Pages share 3 hypotheses
Synthetic Lethality and PARP Inhibition in Neurodegener
mechanism · Pages share 3 hypotheses
synaptic-vesicle-cycling-neurodegeneration
mechanism · Pages share 3 hypotheses
SUMOylation in Neurodegeneration
mechanism · Pages share 3 hypotheses
Show 10 more